These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 38312833)

  • 1. Critical role of FGF21 in diabetic kidney disease: from energy metabolism to innate immunity.
    Liang Y; Chen Q; Chang Y; Han J; Yan J; Chen Z; Zhou J
    Front Immunol; 2024; 15():1333429. PubMed ID: 38312833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGF21 and Chronic Kidney Disease.
    Salgado JV; Goes MA; Salgado Filho N
    Metabolism; 2021 May; 118():154738. PubMed ID: 33617873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of fibroblast growth factor 21 in diabetic cardiomyopathy.
    Zhang X; Yang L; Xu X; Tang F; Yi P; Qiu B; Hao Y
    Heart Fail Rev; 2019 Nov; 24(6):1005-1017. PubMed ID: 31175491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic Variants Flanking the
    Yu W; Zhu H; Chen X; Gu X; Zhang X; Shen F; Jia W; Hu C
    J Diabetes Res; 2019; 2019():9387358. PubMed ID: 31205953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibroblast growth factor 21 in chronic kidney disease.
    Suassuna PGA; de Paula RB; Sanders-Pinheiro H; Moe OW; Hu MC
    J Nephrol; 2019 Jun; 32(3):365-377. PubMed ID: 30430412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial Contribution to Inflammation in Diabetic Kidney Disease.
    Mitrofanova A; Fontanella AM; Burke GW; Merscher S; Fornoni A
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attenuation of hyperlipidemia- and diabetes-induced early-stage apoptosis and late-stage renal dysfunction via administration of fibroblast growth factor-21 is associated with suppression of renal inflammation.
    Zhang C; Shao M; Yang H; Chen L; Yu L; Cong W; Tian H; Zhang F; Cheng P; Jin L; Tan Y; Li X; Cai L; Lu X
    PLoS One; 2013; 8(12):e82275. PubMed ID: 24349242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipin-1 deficiency deteriorates defect of fatty acid β-oxidation and lipid-related kidney damage in diabetic kidney disease.
    Lin S; Wang L; Jia Y; Sun Y; Qiao P; Quan Y; Liu J; Hu H; Yang B; Zhou H
    Transl Res; 2024 Apr; 266():1-15. PubMed ID: 37433392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of inflammation in diabetic kidney disease.
    Jung SW; Moon JY
    Korean J Intern Med; 2021 Jul; 36(4):753-766. PubMed ID: 34237822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broadening horizons: the contribution of mitochondria-associated endoplasmic reticulum membrane (MAM) dysfunction in diabetic kidney disease.
    Liu Y; Qiao Y; Pan S; Chen J; Mao Z; Ren K; Yang Y; Feng Q; Liu D; Liu Z
    Int J Biol Sci; 2023; 19(14):4427-4441. PubMed ID: 37781026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What's New in the Molecular Mechanisms of Diabetic Kidney Disease: Recent Advances.
    Watanabe K; Sato E; Mishima E; Miyazaki M; Tanaka T
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights into the role of immunity and inflammation in diabetic kidney disease in the omics era.
    Hu X; Chen S; Ye S; Chen W; Zhou Y
    Front Immunol; 2024; 15():1342837. PubMed ID: 38487541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innate immunity in diabetic kidney disease.
    Tang SCW; Yiu WH
    Nat Rev Nephrol; 2020 Apr; 16(4):206-222. PubMed ID: 31942046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid deposition and metaflammation in diabetic kidney disease.
    Mitrofanova A; Fontanella AM; Merscher S; Fornoni A
    Curr Opin Pharmacol; 2020 Dec; 55():60-72. PubMed ID: 33137677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in understanding the innate immune-associated diabetic kidney disease.
    Wan S; Wan S; Jiao X; Cao H; Gu Y; Yan L; Zheng Y; Niu P; Shao F
    FASEB J; 2021 Feb; 35(2):e21367. PubMed ID: 33508160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term adjustment of hepatic lipid metabolism after chronic stress and the role of FGF21.
    Dille M; Nikolic A; Wahlers N; Fahlbusch P; Jacob S; Hartwig S; Lehr S; Kabra D; Klymenko O; Al-Hasani H; Kotzka J; Knebel B
    Biochim Biophys Acta Mol Basis Dis; 2022 Jan; 1868(1):166286. PubMed ID: 34624498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast growth factor 21 in cardio-metabolic disorders: a systematic review and meta-analysis.
    Lakhani I; Gong M; Wong WT; Bazoukis G; Lampropoulos K; Wong SH; Wu WKK; Wong MCS; Ong KL; Liu T; Tse G;
    Metabolism; 2018 Jun; 83():11-17. PubMed ID: 29410351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probiotics improve renal function, glucose, lipids, inflammation and oxidative stress in diabetic kidney disease: a systematic review and meta-analysis.
    Dai Y; Quan J; Xiong L; Luo Y; Yi B
    Ren Fail; 2022 Dec; 44(1):862-880. PubMed ID: 35611435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor 21 regulates glucose metabolism in part by reducing renal glucose reabsorption.
    Li S; Wang N; Guo X; Li J; Zhang T; Ren G; Li D
    Biomed Pharmacother; 2018 Dec; 108():355-366. PubMed ID: 30227329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating levels of fibroblast growth factor 21 in early-stage diabetic kidney disease.
    Esteghamati A; Khandan A; Momeni A; Behdadnia A; Ghajar A; Nikdad MS; Noshad S; Nakhjavani M; Afarideh M
    Ir J Med Sci; 2017 Aug; 186(3):785-794. PubMed ID: 28181108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.